A prospective study comparing endoscopic subcutaneous mastectomy plus immediate reconstruction with implants and breast conserving surgery for breast cancer

• Published in: Chinese medical journal 2009-12, Vol.122 (24), p.2945-2950
• Main Authors: Fan, Lin-Jun, Jiang, Jun, Yang, Xin-Hua, Zhang, Yi, Li, Xing-Gang, Chen, Xian-Chun, Zhong, Ling
• Format: Article
• Language: English
• Subjects: Adult; Breast Neoplasms - surgery; Female; Humans; Mastectomy, Segmental - adverse effects; Mastectomy, Segmental - methods; Mastectomy, Subcutaneous - adverse effects; Mastectomy, Subcutaneous - methods; Middle Aged; Prospective Studies; Reconstructive Surgical Procedures - adverse effects; Reconstructive Surgical Procedures - methods; 乳腺癌; 传输服务; 手术治疗; 植入物; 环境管理; 病理特点
• ISSN: 0366-6999; 2542-5641
• DOI: 10.3760/cma.j.issn.0366-6999.2009.24.005

Background Breast conserving surgery （BCS） has been the standard surgical procedure for the treatment of early breast cancer. Endoscopic subcutaneous mastectomy （ESM） plus immediate reconstruction with implants is an emerging procedure. The objective of this prospective study was to evaluate the clinical outcomes of these two surgical procedures in our clinical setting. Methods From March 2004 to October 2007, 43 patients with breast cancer underwent ESM plus axillary lymph node dissection and immediate reconstruction with implants, while 54 patients underwent BCS. The clinical and pathological characteristics, surgical safety, and therapeutic effects were compared between the two groups. Results There were no significant differences in the age, clinical stage, histopathologic type of tumor, operative blood loss, postoperative drainage time, and postoperative complications between the two groups （P 〉0.05）. The postoperative complications were partial necrosis of the nipple and superficial skin flap in the ESM patients, and hydrops in the axilla and residual cavity in the BCS patients. There was no significant difference in the rate of satisfactory postoperative cosmetic outcomes between the ESM （88.4%, 38/43） and BCS （92.6%, 50/54） patients （P 〉0.05）. During follow-up of 6 months to 4 years, all patients treated with ESM were disease-free, but 3 patients who underwent BCS had metastasis or recurrence -- one of these patients died of multiple organ metastasis. Conclusions After considering the wide indications for use, high surgical safety, and favorable cosmetic outcomes, we conclude that ESM plus axillary lymph node dissection and immediate reconstruction with implants -- the new surgery of choice for breast cancer -- warrants serious consideration as the prospective next standard surgical procedure.